Supernus Pharmaceuticals Inc (FRA:S49)
€ 34.6 0.6 (1.76%) Market Cap: 1.97 Bil Enterprise Value: 1.62 Bil PE Ratio: 34.78 PB Ratio: 2.04 GF Score: 80/100

Q1 2024 Supernus Pharmaceuticals Inc Earnings Call Transcript

May 08, 2024 / 08:30PM GMT
Release Date Price: €28.8 (+2.13%)
Operator

Good afternoon and welcome to the Supernus Pharmaceuticals First Quarter 2024 financial results conference call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. Instructions will follow at that. As a reminder, this conference call is being recorded. I would now like to turn the conference over to Peter Vozzo of ICR Westwicke, Investor Relations Representative super and U.S. pharmaceuticals. You may now begin.

Peter Vozzo
ICR Westwicke - Investor Relations

Thank you, Mark, and good afternoon, everyone, and thank you for joining us today versus host Pharmaceuticals First Quarter 2024 financial results conference call. Today after the close of the market, the company issued a press release announcing these results on the call with me today are six furnaces Chief Executive Officer, Jack Khattar, and Chief Financial Officer, Tim Dec.

Today's call is being made available via the Investor Relations section of the company's website at ir dot supernus.com. During the course of this call,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot